Milestone Pharmaceuticals will present etripamil data at AHA 2025, focusing on its efficacy and safety for PSVT patients.
Quiver AI Summary
Milestone Pharmaceuticals Inc. announced that it will present a poster at the American Heart Association Scientific Sessions 2025, taking place from November 7-10 in New Orleans. The presentation will focus on the efficacy, safety, and tolerability of self-administered etripamil for patients experiencing paroxysmal supraventricular tachycardia (PSVT). Dr. James Ip from Weill Cornell Medicine will present the findings on November 10, 2025. Milestone is a biopharmaceutical company dedicated to developing cardiovascular medicines and has recently submitted a New Drug Application for etripamil to the FDA for treating PSVT.
Potential Positives
- Milestone Pharmaceuticals will present significant data on etripamil's efficacy, safety, and tolerability at a major scientific conference, highlighting its commitment to advancing cardiovascular medicine.
- The presentation at the American Heart Association Scientific Sessions offers a prominent platform for Milestone to reach key stakeholders and potential investors in the biopharmaceutical industry.
- The recent submission of a New Drug Application (NDA) to the FDA for etripamil signals progress in the company’s pipeline and potential future commercialization of this treatment for PSVT.
Potential Negatives
- There is no information on the outcomes of previous trials for etripamil, raising concerns about the drug's efficacy and safety prior to the upcoming AHA presentation.
- The announcement focuses on an upcoming presentation rather than concrete results or milestones already achieved, which may signal a lack of immediate positive developments.
- Potential investors may view the timing of the presentation and ongoing NDA process as a sign of uncertainty regarding FDA approval timelines and the competitive landscape in the cardiovascular market.
FAQ
What is the focus of Milestone Pharmaceuticals Inc.?
Milestone Pharmaceuticals Inc. focuses on developing and commercializing innovative cardiovascular medicines.
When will Milestone Pharmaceuticals present at the AHA Scientific Sessions 2025?
The poster presentation will take place on November 10, 2025, from 10:30 AM to 11:30 AM CST.
What is the topic of the poster presentation at AHA 2025?
The presentation will cover the efficacy, safety, and tolerability of self-administered etripamil for paroxysmal supraventricular tachycardia (PSVT).
Who is presenting the poster at the AHA event?
The poster will be presented by James Ip, M.D., an Associate Professor at Weill Cornell Medicine.
What recent regulatory submission has Milestone Pharmaceuticals made?
Milestone recently submitted a New Drug Application (NDA) to the FDA for etripamil, aimed at treating PSVT.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MIST Hedge Fund Activity
We have seen 21 institutional investors add shares of $MIST stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROPEL BIO MANAGEMENT, LLC added 340,000 shares (+23.4%) to their portfolio in Q2 2025, for an estimated $659,600
- MILLENNIUM MANAGEMENT LLC removed 322,082 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $624,839
- STONEPINE CAPITAL MANAGEMENT, LLC removed 250,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $485,000
- UBS GROUP AG added 211,125 shares (+189.3%) to their portfolio in Q2 2025, for an estimated $409,582
- MORGAN STANLEY removed 148,104 shares (-15.3%) from their portfolio in Q2 2025, for an estimated $287,321
- SIMPLIFY ASSET MANAGEMENT INC. added 140,000 shares (+16.5%) to their portfolio in Q2 2025, for an estimated $271,600
- GOLDMAN SACHS GROUP INC added 119,449 shares (+inf%) to their portfolio in Q2 2025, for an estimated $231,731
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MIST Analyst Ratings
Wall Street analysts have issued reports on $MIST in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 09/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/05/2025
To track analyst ratings and price targets for $MIST, check out Quiver Quantitative's $MIST forecast page.
$MIST Price Targets
Multiple analysts have issued price targets for $MIST recently. We have seen 2 analysts offer price targets for $MIST in the last 6 months, with a median target of $4.5.
Here are some recent targets:
- Mohit Bansal from Wells Fargo set a target price of $4.0 on 09/11/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $5.0 on 06/05/2025
Full Release
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10 t h in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil by patients with episodes of paroxysmal supraventricular tachycardia.
AHA 2025 Presentation Details:
| Poster Presentation Title: | Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials |
| Presenter: | James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital |
| Date and time: | Monday, November 10, 2025, 10:30 – 11:30 AM CST |
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.
Investor Relations
Kevin Gardner, [email protected]
